US 12,357,682 B2
DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA
Jing Zou, Galveston, TX (US); Xuping Xie, Galveston, TX (US); and Pei-Yong Shi, Galveston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Appl. No. 17/273,258
Filed by Board of Regents, the University of Texas System, Austin, TX (US)
PCT Filed Aug. 30, 2019, PCT No. PCT/US2019/049036
§ 371(c)(1), (2) Date Mar. 3, 2021,
PCT Pub. No. WO2020/051080, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/726,813, filed on Sep. 4, 2018.
Prior Publication US 2021/0338794 A1, Nov. 4, 2021
Int. Cl. A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); A61K 2039/5254 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/552 (2013.01)] 6 Claims
OG exemplary drawing
 
1. An immunogenic composition comprising a DNA plasmid comprising from 5′ to 3′ (a) a promoter segment active in a mammalian cell, (b) a cDNA of a live-attenuated Zika virus (ZIKV) genome comprising (i) a 5′ untranslated region, (ii) a coding region for the live-attenuated Zika virus (ZIKV), and (iii) a 3′ untranslated region, (c) a hepatitis delta virus ribzyme (HDVr) segment, and (d) a polyadenylation signal.